Grants Search Results

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to support the pediatric neuro-oncology program and ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The impact that cancer has on a child/teen reaches far beyond the physical ailment. The psychological impact can be just as devastating. Recent studies have shown that 32% of adolescent and young adult patients suffer from symptoms of post-traumatic stress disorder (PTSD). Akron Children's Hospital treats a minimum of 90 newly diagnosed children and adolescents with cancer annually. Akron Children's will assess patient and family experiences during and post cancer treatment. The goal of the study will be to create a uniform infrastructure to formalize pathways to support the emotional needs of patients and their families.

This grant has been funded by and named for The Abbey E. Foltz Fund, a St. Baldrick’s Hero Fund. Abbey was diagnosed with osteosarcoma of the right tibia when she was 14 years old and a freshman in high school. She loved school, spending time with her family and friends and dancing. All that changed as she battled cancer with ongoing treatments and surgeries. Yet through it all, Abbey remained positive, focused on helping others and aspired to be a nurse. Sadly, she passed away while in her first year of college. Her family carries on Abbey’s legacy of making a difference for patients and their families with this Hero Fund by funding childhood cancer research in Northeastern Ohio.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. While facing an epidemic, natural disasters, and a pandemic, Hospital HIMA San Pablo Caguas has served 13-30% of new cancer patients age 0-19 years old in Puerto Rico. Puerto Rico's 99% Hispanic or Latino population has limited access to participation in clinical research. A Clinical Research Associate for childhood cancer research will facilitate an increase in the number of studies, patient participation, and data completion rate.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. In the past, children diagnosed with cancer in the Rio Grande Valley had to travel to cities such as Houston or San Antonio to get state-or-the-art treatment through clinical trials. With St. Baldrick's support physicians at the Vannie Cook Clinic in the Rio Grande Valley now have access to the most advanced trials and latest medications through Children's Oncology Group and other Texas-based clinical trials.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. In El Paso many of the people are Hispanic, underserved in healthcare, and are mostly below the poverty line. Due to these facts, they do not get equal opportunities to participate in clinical research and are disadvantaged. Support from St. Baldrick's will facilitate clinical research in underserved populations with minorities.

This grant supports a Clinical Research Associate for the early phase trial program to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. The University of Illinois at Chicago (UIC), Rush University Medical Center, and John H. Stroger Hospital of Cook County COG Clinical Trials Program exists to meet the needs of an extremely diverse population of patients from birth to 30 years of age (and sometimes beyond) who are currently struggling with cancer or who have survived this terrible disease but are at great risk for many, many long term health problems. UIC, Rush and Stroger Medical Centers anchor the near west side of Chicago and serve incredibly vulnerable patients and families, with the majority of whom having very limited personal resources, medical knowledge, limited English language skills and who have no or public insurance.

This grant is named for the Do It for Dominic Fund which honors the memory of Dominic Cairo who battled non-Hodgkins lymphoma and was a hero to his school and community. His family and friends continue to raise funds and support research in the hopes that no child has to go through what Dominic endured.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Despite breakthroughs in cancer biology, pediatric solid tumors have seen minimal improvement in patient outcomes. Neuroblastoma, the most common solid tumor malignancy of childhood, encapsulates the full spectrum of cancer heterogeneity. Dr. Mosse’s team have shown that a specific ALK inhibitor is far superior than the current targeted therapy being tested in a Children’s Oncology Group Phase 3 trial for patients with an ALK genetic alteration. To ensure that the proper clinical and correlative studies are done to identify all patients whose tumors harbor an ALK genetic alteration using a custom-designed and targeted deep sequence capture panel. In parallel, Dr. Mosse and colleagues will adapt this panel to capture circulating tumor DNA (ctDNA) in the blood, also called “liquid biopsies,” of these patients and follow them over time to learn how they respond to our therapies and if/how their tumors develop resistance. While liquid biopsies have become a validated clinical tool in a subset of adult malignancies, its utility in pediatric cancers remains unproven. Liquid biopsies have the potential to overcome many of the limitations we face with solid tumors, as ctDNA abundance tracks with disease burden, reliably captures tumor genomic heterogeneity, and portends patient outcomes. Dr. Mosse and colleagues hypothesize that there is a critical unmet need to harness minimally invasive ctDNA assays to elucidate actionable targets in high-risk neuroblastoma, monitor response to therapy and disease burden, and establish circulating nucleic acid detection as a clinical biomarker for pediatric solid tumors. This grant is funded through a partnership between the St. Baldrick’s Foundation and the American Cancer Society.

Acute myeloid leukemia (AML) as an aggressive pediatric cancer associated with poor outcomes and few changes in therapies over the past 30 years. The presence of small numbers of persisting leukemia cells after chemotherapy has become an important predictor of leukemia relapse, however, current assays used to detect residual leukemia have limited sensitivity and many patients with “no detectable leukemia” still go on to relapse. This underscores the need to identify and develop novel assays that more accurately determine optimal therapies and that improve upon current leukemia detection approaches for AML. Dr. Meshinchi and colleagues have performed functional genomic profiling (RNA sequencing) in 2000 children, adolescents, and young adults diagnosed with AML over the past 25 years that includes diagnosis, remission, and relapse timepoints. This preliminary data suggests that deep and functional cancer profiling across an unprecedented number of patient samples and timepoints informs relapse risk, enables a precision medicine approach that considers specific alterations within a patient’s specific cancer, and links diagnosis and relapse profiles with the goal of better understanding how/why relapses occur and how best to prevent them. Therefore, Dr. Meshinchi and colleagues plan to leverage this unprecedented dataset to develop an integrated genomic platform that will significantly improve prognostic determination and treatment decisions for children, adolescents, and young adults diagnosed with AML. Successful validation of our assays will therefore fill a critical unmet need in the field of AML, and the resulting product will be an optimized test ready for clinical use.

This grant is funded through a partnership between the St. Baldrick’s Foundation and the American Cancer Society.

Acute Myeloid Leukemia (AML) is a heterogeneous disease characterized by malignant clonal expansion of undifferentiated progenitor cells. The relapse and refractory AML is one of the biggest challenge faced by clinicians as significant proportion of patients within this category have very poor outcome. Persistence of leukemic stem cells has been associated with higher risk of relapse, additionally these leukemic stem cells also show drug resistance characteristics. Dr. Lamba’s team has recently developed a gene-expression based pediatric leukemic stemness score and drug resistance score that has shown promising results in not only identifying patients with higher risk of relapse and poor outcome but is also suggestive of response post-transplant. Dr. Lamba is also focused on inherited genetic polymorphisms to study pharmacogenomics markers specific to the standard chemotherapy regimen. We recently developed a pharmacogenomic score for are-C the mainstay of AML chemotherapy that associated with treatment outcome and survival. This project seeks to validate the gene expression and genotype-based scores in large cohort of patients treated on a Children’s Oncology Group clinical trial. The results will prepare a sound scientific rationale to incorporate a preemptive testing of patients for genomics based prognostic score that can be incorporated into the risk stratification of patients to guide precision medicine in AML. This grant is funded through a partnership between the St. Baldrick’s Foundation and the American Cancer Society.